677773-32-9

677773-32-9 structure

Name: Etamicastat hydrochloride
Chemical Name: Etamicastat hydrochloride
CAS Number: 677773-32-9
Molecular Formula: C₁₄H₁₆ClF₂N₃OS
Molecular Weight: 347.81100
Catalog: Research Areas Cardiovascular Disease
Create Date: 2017-09-25 13:29:25
Modify Date: 2024-01-16 15:20:26
Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM[1]. Etamicastat can be used in the research of cardiovascular diseases[2].

Name	Etamicastat hydrochloride
Synonyms	(R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydro-2H-imidazole-2-thione hydrochloride (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride

Description	Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM[1]. Etamicastat can be used in the research of cardiovascular diseases[2].
Related Catalog	Research Areas >> Cardiovascular Disease
Target	IC50: 107 nM (DBH)[1]
In Vitro	Etamicastat blocks the hERG current amplitude with an IC50 value of 44 μg/mL (141 μM)[2].
In Vivo	Etamicastat (100 mg/kg; administered intraperitoneally) leads to a significant reduction of noradrenaline levels in heart with concomitant increasing in dopamine levels[1]. Etamicastat (50 mg/kg; a single oral administration) exhibits moderate oral bioavailability (64%), Cmax (4.9 nM), and terminal elimination half-lives (T1/2=3.7 h) in male Wistar rats[1]. Animal Model: NMRi mice[1] Dosage: 100 mg/kg Administration: Administered intraperitoneally Result: Led to a significant reduction of noradrenaline levels (36% control) in heart with concomitant increasing in dopamine levels (850% of control). Animal Model: Male Wistar rats[1] Dosage: 50 mg/kg (Pharmacokinetic Analysis) Administration: Orally administered with at a dose volume of 10 mL/kg Result: Oral bioavailability (64%), Cmax (4.9 nM), and (T1/2=3.7 h).
References	[1]. Loureiro AI, et al. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol. 2014 Oct 5;740:285-94. [2]. ManuelVaz-da-Silva, et al. Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. IJC Metabolic & Endocrine. 2015 Jun; (7): 10-24

Molecular Formula	C₁₄H₁₆ClF₂N₃OS
Molecular Weight	347.81100
Exact Mass	347.06700
PSA	88.06000
LogP	4.00360

Precursor 0
DownStream 1
760173-05-5

677773-32-9	1406-14-0
6138-79-0	127228-87-9
143851-98-3	929-73-7
65546-09-0	1135280-78-2
56-99-5	1406-02-6
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
2172581-60-9	1018584-77-4
1375289-11-4	849349-65-1